MIAMI, FL – ( April 12, 2017) – Biorasi, LLC. announced today that their Vice President of Drug Safety and Pharmacovigilance, Mark Vieder, RPh, MBA, has been officially selected to join the faculty of the DIA (founded as the Drug Information Association). This appointment comes as a great honor for Mr. Vieder, and for Biorasi, as another testament to the talented executive team the company is building.
The DIA faculty is a prestigious appointment that is only offered to senior and highly respected members of the pharmaceutical and biotech profession to facilitate the DIA’s mission of education and development.
Mr. Vieder was selected for his accomplishments over a long career that has included leadership positions across the public and private spheres of pharmaceutical research and development. Mr. Vieder‘s experience in the pharmaceutical sector includes Parke-Davis/Warner-Lambert, Pfizer, and Regeneron, where he was involved with drug safety and pharmacovigilance.
His public sector experience includes nearly two decades with the FDA, where he led the post-marketing adverse event database (FAERS). Mr. Vieder’s experience also led to his becoming a trusted resource for many centers inside the agency, including the Office of Surveillance & Epidemiology, the Office of New Drugs, Office of Generic Drugs, Office of Regulatory affairs, and the Office of Compliance.
Mark Vieder currently works as the Vice President, Drug Safety & Pharmacovigilance at Biorasi. His knowledge and experience leads the company in transforming safety and compliance from a must-have to becoming an industry-leading driver of innovation in clinical trials.
“It’s a tremendous privilege to join such a select group of pharmaceutical professionals,” said Mark Vieder. “I’m honored to have my experience recognized among this esteemed group of industry leaders, and by an organization as respected in our industry as the DIA. I hope to contribute meaningfully to the DIA’s mission of fostering innovation for improved health and well-being world-wide.”
Biorasi is widely recognized as a leading contract research organization (CRO), delivering Clinical Research Optimized™ in some of the most complex trials in the industry. Equipped with TALOS™, our innovative project management and optimization platform, Biorasi full service project teams have developed numerous drugs, biologics, and devices that received FDA and multi-venue approvals for some of the leading pharmaceutical companies in the world. Biorasi is headquartered in Miami, FL and has regional offices across North America and around the globe.